Skip to main content
Celon Pharma S.A. logo

Celon Pharma S.A. — Investor Relations & Filings

Ticker · CLN ISIN · PLCLNPH00015 LEI · 259400Q0ERJT0NC5DT24 WAR Manufacturing
Open in API
Filings indexed 709 across all filing types
Latest filing 2022-03-11 Share Issue/Capital Cha…
Country PL Poland
Listing WAR CLN

About Celon Pharma S.A.

https://celonpharma.com/en/

Celon Pharma S.A. is an integrated pharmaceutical company that conducts advanced research and manufactures modern drugs. The company is engaged in the development, production, distribution, and marketing of therapeutic solutions. Its primary focus is on developing treatments for cancers, neurological diseases, diabetes, and other metabolic disorders. As a marketing authorization holder, Celon Pharma manages the full product lifecycle, from scientific research and development to commercialization, aiming to improve patient health and quality of life.

Recent filings

Filing Released Lang Actions
Wydanie 30.000 akcji serii C w ramach warunkowego podwyższenia kapitału zakładowego - Content (PL)
Share Issue/Capital Change Classification · 1% confidence The document text, written in Polish, details the issuance of 30,000 Series C shares following the exercise of subscription warrants as part of an incentive program. It explicitly mentions the increase in the company's share capital ('podwyższenia kapitału zakładowego Spółki') and provides the new breakdown of the total share capital and the total number of votes. This content directly relates to changes in the company's capital structure and share issuance, which aligns precisely with the definition of 'Share Issue/Capital Change' (SHA). The document is a formal announcement of this capital event, not a general regulatory filing (RNS) or a report publication announcement (RPA), as it contains the substantive details of the capital change itself.
2022-03-11 Polish
Zawarcie umowy w sprawie zakupu licencji - Content (PL)
Regulatory Filings Classification · 1% confidence The document text describes the acquisition of a non-exclusive patent license agreement ('Umowa') by Celon Pharma S.A. from Salk Institute for Biological Studies concerning methods for treating metabolic disorders, specifically diabetes (Type II) using an FGF1 analog (M43). This transaction secures commercialization rights for a key asset. This type of corporate action, involving the acquisition of intellectual property rights or significant licensing agreements that impact future commercial potential, falls under the category of corporate transactions or strategic updates. Since it directly relates to securing rights for a drug candidate, it is most closely aligned with 'Capital/Financing Update' (CAP) if it were a financing event, or more generally, a significant strategic transaction. Given the options, the acquisition of a license that is a 'significant element closing the full commercialization rights' for a drug candidate is best classified as a major strategic transaction. However, none of the codes perfectly match 'Licensing Agreement Acquisition'. Reviewing the definitions: - 10-K/IR: Not a full annual/interim report. - ER/MDA: Not an earnings release or management discussion. - CAP: Usually fundraising/financing, but sometimes strategic deals are included if they change the capital structure or funding needs significantly. This is a licensing deal, not direct financing. - TAR: M&A/Takeover bids, which this is not. - LTR: Legal proceedings, which this is not. The closest fit among the provided options for a major strategic agreement securing commercial rights for a key product, especially when considering the context of drug development milestones, is often grouped with financing/capital structure changes or significant corporate events. Given the options, and recognizing this as a material event impacting the company's assets and future revenue streams, 'Capital/Financing Update' (CAP) is the most plausible category for a significant licensing deal that secures commercialization rights, although 'Regulatory Filings' (RNS) could be a fallback if the event itself is not explicitly covered. Since this is a detailed announcement of a material agreement, it is a significant corporate event. In many databases, major licensing deals are categorized under financing/capital structure updates or strategic transactions. I will classify it as CAP as it secures the commercial rights necessary for future value realization, similar to a capital investment in an asset. Revisiting the definitions, there is no specific 'Licensing/IP Acquisition' code. The document details a material agreement securing commercial rights for a drug candidate. This is a significant corporate event. If it were a simple announcement of the report itself, it would be RPA/RNS. Since it is the substance of the event, and it relates to securing the commercial future of a key asset, CAP (Capital/Financing Update) is chosen as the best fit among the available strategic transaction codes, although it is a weak fit.
2022-02-22 Polish
Oświadczenie KDPW w sprawie zawarcia umowy o rejestrację akcji serii C Spółki - Content (PL)
Share Issue/Capital Change Classification · 1% confidence The document text is very short (674 characters) and announces an action taken by the Polish Central Securities Depository (KDPW) regarding the registration of 2,000,000 Series C shares following the exercise of subscription warrants. This relates to a change in the capital structure (issuance of shares via warrants). Since it is a specific announcement about the registration of newly issued shares related to a capital event, it fits best under 'Share Issue/Capital Change' (SHA). It is not a general regulatory filing (RNS) because it concerns a specific capital structure event.
2022-02-16 Polish
Rozpoczęcie badania klinicznego II fazy CPL'280 w leczeniu cukrzycy typu II - Content (PL)
Regulatory Filings Classification · 1% confidence The document text is a short announcement in Polish from Zarząd Celon Pharma S.A. regarding the enrollment of the first patient in a Phase II clinical trial for a compound (CPL'280) for diabetes treatment. It details the purpose, scope, and funding source (NCBR/POIR) of the trial. This content relates to the development pipeline and clinical progress, which is typically disclosed as a general regulatory announcement or a specific update on R&D activities. Since there is no specific category for 'Clinical Trial Update' and it is not a full financial report (10-K, IR), earnings release (ER), or management discussion (MDA), it falls best under the general 'Regulatory Filings' (RNS) category, as it is a material, non-financial operational update required for disclosure. The document length is very short (881 chars), confirming it is an announcement, not a comprehensive report.
2022-01-21 Polish
Uzupełnienie informacji dotyczącej europejskiego patentu w zakresie formulacji inhalacyjnej esketaminy i rozszerzenie ochrony patentowej poza leczenie depresji lekoopornej - Content (PL)
Legal Proceedings Report Classification · 1% confidence The document is a short announcement (1218 characters) written in Polish, referencing a prior current report ('raport bieżący nr 52/2021'). It details the receipt of specifications for two European patents (EP 3 731 815 B1 and EP 3 505 157 B1) related to esketamine inhalation formulation. This is a specific regulatory update concerning intellectual property and potential commercialization, but it is not a comprehensive financial report (like 10-K or IR) nor a standard management change (MANG) or dividend notice (DIV). Since it is a specific, non-standard regulatory update that doesn't fit the other specific categories (like DIRS, DVA, CAP, etc.), the most appropriate classification is the general regulatory fallback category, RNS (Regulatory Filings). The short length and nature of reporting a specific event also align with the characteristics of an RNS filing rather than a detailed report.
2022-01-12 Polish
Terminy przekazywania raportów okresowych w 2022 roku - Content (PL)
Report Publication Announcement Classification · 1% confidence The document text is very short (565 characters) and explicitly states the dates when various periodic reports (annual, quarterly, semi-annual) for the year 2022 will be released by the Management Board of Celon Pharma S.A. It cites Polish financial regulation (§ 80 ust. 1 Rozporządzenia Ministra Finansów). Since this document is an announcement *about* the publication schedule of future reports, rather than the reports themselves, it fits the definition of a Report Publication Announcement (RPA). This aligns with the 'MENU VS MEAL' rule, as it announces the publication rather than being the full report.
2022-01-03 Polish

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.